TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma

被引：0

作者：

Hideaki Bando

Daisuke Kotani

Takahiro Tsushima

Hiroki Hara

Shigenori Kadowaki

Ken Kato

Keisho Chin

Kensei Yamaguchi

Shun-ichiro Kageyama

Hidehiro Hojo

Masaki Nakamura

Hidenobu Tachibana

Masashi Wakabayashi

Miki Fukutani

Yosuke Togashi

Nozomu Fuse

Hiroyoshi Nishikawa

Takashi Kojima

机构：

[1] Aichi Cancer Center Hospital,Department of Clinical Oncology

[2] National Cancer Center Hospital East,Department of Gastroenterology and Gastrointestinal Oncology

[3] Division of Gastrointestinal Oncology Shizuoka Cancer Center,Department of Gastroenterology

[4] Saitama Cancer Center,Department of Gastrointestinal Medical Oncology

[5] National Cancer Center Hospital,Department of Gastroenterological Medicine

[6] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Division of Radiation Oncology and Particle Therapy

[7] National Cancer Center Hospital East,Clinical Research Support Office

[8] National Cancer Center Hospital East,Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center

[9] National Cancer Center Hospital East,undefined

来源：

BMC Cancer | / 20卷

关键词：

Unresectable locally advanced; Esophageal squamous cell carcinoma; Chemoradiotherapy; Atezolizumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma
Bando, Hideaki
Kotani, Daisuke
Tsushima, Takahiro
Hara, Hiroki
Kadowaki, Shigenori
Kato, Ken
Chin, Keisho
Yamaguchi, Kensei
Kageyama, Shun-ichiro
Hojo, Hidehiro
Nakamura, Masaki
Tachibana, Hidenobu
Wakabayashi, Masashi
Fukutani, Miki
Togashi, Yosuke
Fuse, Nozomu
Nishikawa, Hiroyoshi
Kojima, Takashi
BMC CANCER, 2020, 20 (01)
[2] TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.
Bando, Hideaki
Kotani, Daisuke
Tsushima, Takahiro
Hara, Hiroki
Kadowaki, Shigenori
Kato, Ken
Chin, Keisho
Yamaguchi, Kensei
Kageyama, Shun-ichiro
Hojo, Hidehiro
Wakabayashi, Masashi
Fukutani, Miki
Togashi, Yosuke
Fuse, Nozomu
Nishikawa, Hiroyoshi
Kojima, Takashi
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)
Bando, H.
Kumagai, S.
Kotani, D.
Saori, M.
Habu, T.
Tsushima, T.
Hara, H.
Kadowaki, S.
Kato, K.
Chin, K.
Yamaguchi, K.
Kageyama, S-I.
Hojo, H.
Nakamura, M.
Tachibana, H.
Wakabayashi, M.
Fukutani, M.
Fuse, N.
Nishikawa, H.
Kojima, T.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1102 - S1103
[4] Atezolizumab following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
Ooki, Akira
Chin, Keisho
Bando, Hideaki
Kumagai, Shogo
Kotani, Daisuke
Mishima, Saori
Habu, Takumi
Tsushima, Takahiro
Hara, Hiroki
Kadowaki, Shigenori
Kato, Ken
Kensei, Yamaguchi
Kageyama, Shun-Ichiro
Hojo, Hidehiro
Nakamura, Masaki
Tachibana, Hidenobu
Wakabayashi, Masashi
Fukui, Makoto
Fuse, Nozomu
Nishikawa, Hiroyoshi
Kojima, Takashi
ANNALS OF ONCOLOGY, 2023, 34 : S1381 - S1381
[5] Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma – a multicenter phase 2 trial (EPOC1802)
Hideaki Bando
Shogo Kumagai
Daisuke Kotani
Saori Mishima
Takuma Irie
Kota Itahashi
Yosuke Tanaka
Takumi Habu
Sayuri Fukaya
Masaki Kondo
Takahiro Tsushima
Hiroki Hara
Shigenori Kadowaki
Ken Kato
Keisho Chin
Kensei Yamaguchi
Shun-ichiro Kageyama
Hidehiro Hojo
Masaki Nakamura
Hidenobu Tachibana
Masashi Wakabayashi
Makoto Fukui
Nozomu Fuse
Shohei Koyama
Hiroyuki Mano
Hiroyoshi Nishikawa
Kohei Shitara
Takayuki Yoshino
Takashi Kojima
Nature Cancer, 2025, 6 (3) : 445 - 459
[6] Investigation of predictive biomarkers in patients treated with atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802).
Bando, Hideaki
Kumagai, Shogo
Kotani, Daisuke
Mishima, Saori
Habu, Takumi
Tsushima, Takahiro
Hara, Hiroki
Kadowaki, Shigenori
Kato, Ken
Chin, Keisho
Yamaguchi, Kensei
Kageyama, Shun-ichiro
Hojo, Hidehiro
Nakamura, Masaki
Hidenobu, Tachibana
Wakabayashi, Masashi
Fukui, Makoto
Fuse, Nozomu
Nishikawa, Hiroyoshi
Kojima, Takashi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 416 - 416
[7] Cetuximab plus chemoradiation with cisplatin and 5-fluorouracil (5-FU) in locally advanced unresectable esophageal squamous cell carcinoma.
Sunpaweravong, P.
Sunpaweravong, S.
Sangthawan, D.
Pinaikul, S.
Attasaranya, S.
Dechaphunkul, A.
Mitarnun, W.
Fungthammasarn, T.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[8] A prospective study of camrelizumab monotherapy following definitive concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell cancer
Wang, J.
Cheng, Y.
Wu, Y.
Cao, F.
Liu, Q.
Gao, G.
ANNALS OF ONCOLOGY, 2021, 32 : S838 - S838
[9] Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study
Hihara, J.
Hamai, Y.
Emi, M.
Murakami, Y.
Kenjo, M.
Nagata, Y.
Okada, M.
DISEASES OF THE ESOPHAGUS, 2017, 30 (07): : 1115 - 1120
[10] Efficacy and safety of definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma
Habu, Takumi
Bando, Hideaki
Kumanishi, Ryosuke
Ogata, Takatsugu
Fujisawa, Takeshi
Kumagai, Shogo
Fujiwara, Hisashi
Mishima, Saori
Kotani, Daisuke
Nakamura, Masaki
Hojo, Hidehiro
Yoda, Yusuke
Koyama, Shohei
Nishikawa, Hiroyoshi
Yano, Tomonori
Fujita, Takeo
Kadowaki, Shigenori
Muro, Kei
Kinoshita, Takahiro
Kojima, Takashi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

← 1 2 3 4 5 →